16 September 2026 editorial review · Trial
DIAGNODE-3: Intralymphatic GAD-alum in HLA DR3-DQ2 recent-onset T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: No new discrepancy identified in the reviewed summary, stated design, primary endpoint and eligibility against the available registry. This is a bounded protocol comparison, not confirmation of efficacy.
Registry: NCT05018585. Registered endpoint checked: Beta cell function (Baseline to 15 months); Glycemic control (Baseline to 15 months). Eligibility check: Registry age 12 Years to 28 Years; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Limits: No usable primary abstract was independently recovered in this pass for this record. Protocol/design wording was assessed; any existing detailed sponsor, conference or historical outcome claims require their cited source and were not independently certified through full-text review.